Advertisement
Advertisement
NRIX
Nurix Therapeutics, Inc. Common stock
26.91
USDSponsored
+0.28
+1.03%
Aug 13, 15:43 UTC -4
Open
NRIX Earnings Reports
Positive Surprise Ratio
NRIX beat 10 of 24 last estimates.
42%
Next Report
Date of Next Report
Oct 07, 2026
Estimate for Q3 26 (Revenue/ EPS)
$19.09M
/-$0.61
Implied change from Q2 26 (Revenue/ EPS)
+111.05%
/-24.69%
Implied change from Q3 25 (Revenue/ EPS)
+141.77%
/-40.78%
Nurix Therapeutics, Inc. Common stock earnings per share and revenue
On Jul 09, 2026, NRIX reported earnings of -0.81 USD per share (EPS) for Q2 26, missing the estimate of -0.73 USD, resulting in a -10.78% surprise. Revenue reached 9.04 million, compared to an expected 16.49 million, with a -45.17% difference. The market reacted with a -6.60% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.61 USD, with revenue projected to reach 19.09 million USD, implying an decrease of -24.69% EPS, and increase of 111.05% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.89
Actual
-$0.77
Surprise
+13.99%
CorMedix Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.24
Actual
$0.28
Surprise
+19.44%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ADC Therapeutics SA
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+49.12%
Pelthos Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.10
Actual
-$6.62
Surprise
-112.99%
MiNK Therapeutics, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.61
Actual
-$0.62
Surprise
-1.31%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
Biofrontera Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.05
Surprise
+53.31%
FAQ
What were Nurix Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Nurix Therapeutics, Inc. Common stock reported EPS of -$0.81, missing estimates by -10.78%, and revenue of $9.04M, -45.17% below expectations.
How did the market react to Nurix Therapeutics, Inc. Common stock's Q2 2026 earnings?
The stock price moved down -6.6%, changed from $24.69 before the earnings release to $23.06 the day after.
When is Nurix Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for Oct 07, 2026.
What are the forecasts for Nurix Therapeutics, Inc. Common stock's next earnings report?
Based on 10
analysts, Nurix Therapeutics, Inc. Common stock is expected to report EPS of -$0.61 and revenue of $19.09M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement